akaggie05 said:
Bump for any Coronavirus plays... who's got em?
I've got 50 shares of NVAX just to see what happens.
akaggie05 said:
Bump for any Coronavirus plays... who's got em?
what is the story on this. call/put ratio is extremely bullish09Ag said:
Not messing around with Corona stuff. My big position AIMT is due for FDA decision at any moment this week, however.
Their picks are all doing well today.HustlerAggie said:Depends on how bad it gets (or how much fear is ginned up), but some to look at:akaggie05 said:
Bump for any Coronavirus plays... who's got em?
https://www.fool.com/investing/2020/01/26/what-to-expect-in-pfizers-q3-earnings-update.aspx
Looks like it is up another 10.43% in after-hours trading.akaggie05 said:
Pulled the trigger on 1000 shares of INO today. We shall see...
Jet Black said:
TCON is one of I have seen a couple different places but I don't know much about it.
Did anyone hold on to VKTX? Nice move today.Ranger222 said:
Viking Therapeutics (VKTX) announced an offering of stock after the close yesterday. This is a bit of surprise since they had just offered to raise money just a month or two back. However, there seems to be a strong demand for the stock and the offering will be priced at around ~$5. It will be interesting to see which investors end up buying the offering. I would wait till we see 13Gs on increased ownership positions to truly know the sentiment of the stock, but all signs are pointing positive. Just look at the run MDGL has done recently, a competitor of VKTX. I'm thinking about doubling my position here.
TGTX announced data today for Phase II trial in MS with Ublituximab. This is a look at the data after 24 weeks, with the trail expected to go 52. 97.5% of subjects failed to have a relapse after 24 weeks. The MS space is big, and could present a $1 billion opportunity for the company. Entry into the MS area still is not factored into the valuation of the company, as most of the valuation is considered in their hematology programs. This name is going to start gaining buzz again, and could be worth the long term gamble. I should point out that one of the risks of the company is their management, who some view in a negative light. I think ultimately they will be bought out. Data announcement here.
During this market pullback, I'm looking to start some positions in CRISPR stocks. These are longterm plays as they are just beginning to enter into the clinic. My favorite is EDIT as it has some linkage to Celgene and Juno, as well as the only CRISPR company that is tackling eye diseases, the easiest and maybe quickest path for their FDA approval IMO.